ID
31183
Beskrivning
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Please record all concomitant medications and transfusions from the time of study entry through the Week 13 visit. Include study-required medications (i.e. Lugol's solution or potassium iodide, paracetamol, and diphenhydramine).
Nyckelord
Versioner (1)
- 2018-07-25 2018-07-25 -
Rättsinnehavare
see clinicaltrials.gov
Uppladdad den
25 juli 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755
Concomitant Medications & Transfusions
- StudyEvent: ODM
Similar models
Concomitant Medications & Transfusions
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C2360065 (UMLS CUI [1,2])
C0456388 (UMLS CUI [1,3])
C3174092 (UMLS CUI [1,2])
C1519795 (UMLS CUI [1,2])
C0013153 (UMLS CUI [1,2])
C3476109 (UMLS CUI [1,2])
Inga kommentarer